Oxford Biodynamics PLC (OBD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oxford Biodynamics PLC (OBD) has a cash flow conversion efficiency ratio of -2.475x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.76 Million ≈ $-336.06 USD) by net assets (GBX1.12 Million ≈ $135.78 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oxford Biodynamics PLC - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Oxford Biodynamics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OBD total liabilities for a breakdown of total debt and financial obligations.
Oxford Biodynamics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oxford Biodynamics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kiliaro AB
ST:KILI
|
2.808x |
|
Catalyst Media Group PLC
LSE:CMX
|
-0.002x |
|
Slate Grocery REIT
TO:SGR-U
|
0.019x |
|
NB Distressed Debt New Glb
LSE:NBDG
|
-0.006x |
|
W.H.Ireland Group
LSE:WHI
|
-0.090x |
|
STORA ENSO OYJ R (RE-REG)
F:ENUN
|
0.025x |
|
Critical Metals Plc
LSE:CRTM
|
-0.534x |
|
Qlosr Group AB Series B
ST:QLOSR-B
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Oxford Biodynamics PLC (2013–2025)
The table below shows the annual cash flow conversion efficiency of Oxford Biodynamics PLC from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see OBD market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | GBX1.12 Million ≈ $135.78 |
GBX-7.71 Million ≈ $-937.96 |
-6.908x | -195.95% |
| 2024-09-30 | GBX4.36 Million ≈ $530.24 |
GBX-10.17 Million ≈ $-1.24K |
-2.334x | -67.53% |
| 2023-09-30 | GBX6.05 Million ≈ $736.72 |
GBX-8.44 Million ≈ $-1.03K |
-1.393x | +30.35% |
| 2022-09-30 | GBX2.59 Million ≈ $314.88 |
GBX-5.18 Million ≈ $-629.89 |
-2.000x | -126.23% |
| 2021-09-30 | GBX6.69 Million ≈ $814.34 |
GBX-5.92 Million ≈ $-720.05 |
-0.884x | -253.08% |
| 2020-09-30 | GBX13.58 Million ≈ $1.65K |
GBX-3.40 Million ≈ $-413.80 |
-0.250x | -94.01% |
| 2019-09-30 | GBX17.59 Million ≈ $2.14K |
GBX-2.27 Million ≈ $-276.32 |
-0.129x | -33.26% |
| 2018-09-30 | GBX20.05 Million ≈ $2.44K |
GBX-1.94 Million ≈ $-236.29 |
-0.097x | +26.40% |
| 2017-09-30 | GBX11.60 Million ≈ $1.41K |
GBX-1.53 Million ≈ $-185.67 |
-0.132x | +24.40% |
| 2016-09-30 | GBX7.74 Million ≈ $942.10 |
GBX-1.35 Million ≈ $-164.01 |
-0.174x | -28.08% |
| 2015-09-30 | GBX9.04 Million ≈ $1.10K |
GBX-1.23 Million ≈ $-149.53 |
-0.136x | -67.82% |
| 2014-09-30 | GBX5.24 Million ≈ $636.95 |
GBX-424.00K ≈ $-51.59 |
-0.081x | -225.24% |
| 2013-09-30 | GBX2.94 Million ≈ $357.47 |
GBX190.00K ≈ $23.12 |
0.065x | -- |
About Oxford Biodynamics PLC
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor i… Read more